Navigation Links
Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
Date:5/20/2008

lf of this year.

"There are still significant unmet needs in the treatment of COPD. These efficacy and safety data from the Phase II trials are very encouraging," said Lawrence S. Olanoff, M.D., Ph.D., President and Chief Operating Officer of Forest Laboratories. "We look forward to the completion of ACCLAIM I & II trials and continuing the clinical development of aclidinium for the treatment of COPD."

Additional Clinical Data

Three additional clinical trials assessing the safety and pharmacokinetics of aclidinium were also presented at this meeting.

A randomized, double-blind, placebo- and active-controlled clinical trial evaluating the cardiovascular safety and pharmacokinetics of aclidinium (200 or 800 mcg) in 272 healthy subjects, showed no effect on QT interval at doses up to 800 mcg. Furthermore, aclidinium was well-tolerated, with most adverse events being of mild intensity, related to electrode attachment, and of similar incidence across treatment groups. Maximum concentration of aclidinium was reached 5 to 30 minutes post-dose and aclidinium was not detectable in the plasma after one hour.

Results of two other randomized, placebo-controlled studies, each in 16 healthy subjects, were presented. In the first, subjects were exposed to single doses of aclidinium (600 -- 6000 mcg) and placebo to determine pharmacokinetics, safety and tolerability, and maximum tolerated dose. For all doses, aclidinium was undetectable in plasma beyond 3 hours post-dose. Aclidinium was well tolerated across this dosage range, with headache (n=10) and fatigue (n=5) being the most frequently reported adverse events. No serious adverse events were reported. The second study assessed the safety, tolerability, and pharmacokinetics of aclidinium after multiple doses. Subjects received 5 days of treatment with aclidinium 200, 400, 800 mcg or placebo. Aclidinium was undetectable in plasma after all studied doses beyond 1 hour post-dose. Aclidinium was we
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
2. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
3. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
4. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
5. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
8. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
9. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
10. GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
11. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Oct. 30, 2014   NxStage® Kidney Care, Inc ., ... ), is proud to host the grand opening ceremony of ... 1600 W. 16 th Street on November 20, 2014 ... highly trained medical staff who are committed to providing patients ... life benefits made possible through more flexible dialysis treatment options.   ...
(Date:10/30/2014)... , Oct. 30, 2014 Boston Scientific ... participate in the 2014 Credit Suisse Annual Healthcare Conference ... , AZ.  Dan Brennan , executive vice ... about the company beginning at approximately 8:00 a.m. PT ... A live webcast of the presentation and question and ...
(Date:10/30/2014)... Oct. 30, 2014  The number of retail health ... is growing steadily, thanks to drug store chains, according ... of the economic downturn, retail clinic growth had been ... opportunities, as the number of retail clinics reached nearly ... Retail Clinics Market Overview and 2014 Consumer Survey Results ...
Breaking Medicine Technology:Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3
... TECH ) financial results for the quarter ended September ... earnings were $27.5 million or $.74 per diluted share.  Adjusted ... $.81 per diluted share after adjustment for intangible asset amortization ... written-up to fair value as part of acquisitions completed in ...
... NEW YORK, Oct. 25, 2011 ... research report is available in its ... Nervous System Disorders Therapeutics Market to ... Disorder and Schizophrenia Accounted for Half ...
Cached Medicine Technology:Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 2Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 3Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 4Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 5Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 6Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 7Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 8Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 2Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 3Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 4Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 5Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 6Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 7Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 8Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 9Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 10Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 11Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 12Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 13Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 14Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 15Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 16Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 17Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 18Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 19Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 20
(Date:10/30/2014)... (PRWEB) October 30, 2014 Home Care ... leading provider of non-medical, in-home senior care, is weighing ... increased brain health. , The study, performed by the ... of 60 and 78 over a week-long period and ... to daily physical activity. By examining the structural soundness ...
(Date:10/30/2014)... Fort Lauderdale, FL (PRWEB) October 30, 2014 ... leading US Joint Commission Accredited teleradiology and specialty ... today that in addition to its existing teleradiology ... adding multispecialty second opinion and expert telemedicine services, ... Houston, Texas. , As a result of this ...
(Date:10/30/2014)... The Woodlands, TX (PRWEB) October 30, 2014 ... hospital system, released today its 2014 third quarter ... hospitals across Texas boasted infection rates of only ... also reported patient satisfaction scores exceeding 98 percent. ... this past quarter, which included rising satisfaction scores,” ...
(Date:10/30/2014)... Norton HealthDay Reporter WEDNESDAY, ... plastics, chemical during pregnancy may have effects on genital development ... that baby boys born to moms with greater exposure to ... distance -- the space between the genitals and anus. Anogenital ... marker of exposure to androgens ("male" hormones) during pregnancy. ...
(Date:10/30/2014)... (HealthDay News) -- Americans, opinions about the Affordable Care ... study finds. Democratic voters are strongly in favor ... researchers. Almost three-quarters of Democrats want the next Congress ... Congress to implement the current law, while 44 percent ... Among Independent voters, one-third want the law repealed, and ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:Voters' Views on Obamacare Split Along Party Lines 2
... is one step in a long, slow process of reproductive ... age 40 and declining levels of the hormones estrogen and ... a female., ,Menopause, or the “change of life,” affects ... help women cope up better with menopause, hormone replacement therapy ...
... declared Tuberculosis as an emergency in Africa. It is ... WHO Regional // Committee for Africa comprising health ministers ... in the African region. The deaths have quadrupled in ... adopted today at the end of the Committee's fifty-fifth ...
... expression responsible for extreme farsightedness in people. , ... rare, potentially blinding disorder, is caused // by an ... eye growth and regulates the organ's shape and focus. ... the journal Proceedings of the National Academy of Sciences., ...
... probe for the treatment of brain cancer is the ... of Neurological Disorders at Manipal Hospital in Bangalore. // ... ,Removal of brain tumors surgically leads to enormous ... depends on the surgeon’s skill. By using the new ...
... a report published in the September issue of the ... programs that advocate quick and short working out sessions ... health conditions that can lead to diseases. To prevent ... and strenuous workout sessions are required every week. ...
... shown that use of general anesthesia for heroin detoxification ... detoxification. The study, which came in the latest issue ... // of general anesthesia in these circumstances can also ... heroin withdrawal remains plagued by patient discomfort and high ...
Cached Medicine News:Health News:WHO declares Tuberculosis – ‘An Emergency’ in Afr 2Health News:Genetic Cause For Farsightedness Discovered 2Health News:Radio-guided Neurosurgery for treatment of Brain cancer 2Health News:General Anesthesia For Heroin Detoxification Is No Good 2
The DBIL method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of direct (conjugated) bilirubin in serum and plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum...
Latex agglutination slide test for the qualitative and semi-quantitative determination of Anti-Streptolysin O (ASO) in human serum...
For the quantitative in vitro determination of IgA in serum and plasma. This product is suitable for use on Hitachi 704, 705, 717, 902, 911 and 912....
Medicine Products: